Budesonide suspension for inhalation and preparation method thereof
By adding suspension and acetylcysteine to budesonide suspension, nano-grinding and high-pressure homogenization, the precipitation and stratification problems under the influence of temperature are solved, and the stability of the suspension is improved and inhalation effect, suitable for use in groups such as children and the elderly.
Patent Information
- Application Number
- CN202411207469.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-19
AI Technical Summary
The existing budesonide suspension is prone to precipitation and stratification under temperature changes. It needs to be shaken well before use, and the suspension effect is poor during preparation, which affects the user experience.
Acetylcysteine is used to self-decompose viscosity by adding suspending agents such as sodium carboxymethylcellulose and sodium hyaluronate, and nano-grinding and gradient high-pressure homogenization to improve the suspension and stability of the suspension. Sputum hinders, optimizes particle size distribution and redispersibility.
It significantly improves the stability and suspension effect of the suspension, improves the inhalation effect, and is suitable for use in groups such as children and the elderly, and the particle size distribution and settlement volume ratio are both improved.
Smart Images

Figure CN118975982A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of budesonide suspension preparation, in particular to a budesonide suspension for inhalation and a preparation method thereof. Background Art
[0002] Budesonide is a glucocorticoid with highly effective local anti-inflammatory effects. Currently available dosage forms include inhalation aerosol, inhalation powder, and inhalation suspension. Budesonide suspension for inhalation does not require the patient to initiate the simultaneous coordination of nebulization and inhalation actions, and is therefore particularly suitable for children, the elderly, and other patients who are unable to use inhalation aerosols and inhalation powders well.
[0003] The current budesonide suspension can maintain a certain suspension effect under normal conditions, but the suspension effect will be affected by temperature and precipitation and other phenomena will occur, resulting in suspension concentration stratification, which seriously affects the use of the suspension. At the same time, the existing budesonide suspension is only prepared by simple dispersion, mixing and sterilization. The suspension prepared by dispersion and dissolution has poor suspension effect and is easy to stratify. It needs to be shaken before use, which is troublesome. Therefore, the present invention provides a budesonide suspension for inhalation and a preparation method thereof to solve the problems existing in the prior art. Summary of the invention
[0004] In view of the above problems, the object of the present invention is to provide a budesonide suspension for inhalation and a preparation method thereof. The budesonide suspension for inhalation and the preparation method thereof can make the prepared suspension particles more suspendable and the stability greatly improved by adding a suspending agent. The addition of acetylcysteine amino enables the suspension to automatically dissolve the obstruction of sticky phlegm during atomization inhalation, thereby improving the inhalation effect of the medication population. The suspension effect of the suspension is further increased by nano-grinding after mixing and gradient high-pressure homogenization treatment. The particle size distribution, sedimentation volume ratio, redispersibility and stability of the prepared budesonide suspension are all improved to varying degrees, making it more suitable for absorption by the medication population.
[0005] To achieve the purpose of the present invention, the present invention is achieved through the following technical scheme: a budesonide suspension for inhalation, comprising budesonide, edetate disodium, acetylcysteine, surfactant, sodium chloride, pH regulator, antibacterial agent, suspending agent and water for injection, which are mixed in a mass ratio of 3.5-5.5:0.45-1.25:1.5-3:0.1-0.35:2.4-5.5:3.8-4.8:1.2-1.8:0.8-1.6:75-90.
[0006] A further improvement is that: the budesonide particle size range D 90 Less than 8μm, where D 50 Less than 5μm, D 10Less than 3 μm; the surfactant is polysorbate 80; the pH adjuster is a mixture of citric acid and sodium citrate in a mass ratio of 1.3-1.8:2.5-3.
[0007] A further improvement is that: the antibacterial agent is one or more of ethyl paraben, phenol, phenylethyl alcohol and chlorobutanol; the suspending agent is one or more of sodium carboxymethyl cellulose, polyethylene glycol and sodium hyaluronate.
[0008] A further improvement is that the mass ratio of the budesonide, edetate disodium, acetylcysteine, surfactant, sodium chloride, pH regulator, antibacterial agent, suspending agent and water for injection is 3.8:0.45:1.5:0.2:4.95:3.8:1.3:1.2:82.8.
[0009] A method for preparing a budesonide suspension for inhalation comprises the following steps: Step 1: Preliminary mixing: budesonide, edetate disodium, acetylcysteine, sodium chloride, citric acid and sodium citrate are premixed, and then deionized water is added to dissolve and stir until no precipitate is obtained to obtain a premixed solution; Step 2: Mixing and concentrating: adding polysorbate 80 to the premixed solution and stirring to dissolve to obtain a mixed solution, and then evaporating and concentrating the mixed solution to a viscous liquid; Step 3: sterilization treatment: performing dry heat sterilization on the prepared viscous liquid to obtain a sterile viscous liquid; Step 4: diluting and homogenizing, diluting the sterile viscous liquid with 50% of the total amount of water for injection, and then using a high-pressure homogenizer to perform gradient high-pressure homogenization after sufficient stirring and dissolution to obtain a homogenized suspension, and then adding the antibacterial agent, the suspending agent and the remaining water for injection to the suspension and uniformly mixing to obtain a budesonide suspension; Step 5: Test packaging. Perform particle size distribution, sedimentation volume ratio, redispersibility and stability tests on the prepared budesonide suspension. Once the test results meet the standards, sterile filling can be performed.
[0010] A further improvement is that the premixing in step 1 is to first weigh the materials according to the ratio and add them into a mixing device for stirring and mixing, then place the mixed materials in a nano-grinding device for nano-grinding treatment and sieve to obtain a premix; wherein a 1700-mesh sieve is used for sieving.
[0011] A further improvement is that the specific operation of evaporation and concentration in step 2 is to first introduce the mixed solution into an evaporation tank, then extract the air inside it to make it in a low-pressure state, then start the evaporation tank to heat and evaporate the mixed solution, and then naturally cool the evaporated and concentrated viscous liquid to room temperature for collection, so as to obtain a viscous liquid.
[0012] A further improvement is that in step three, the dry heat sterilization is to first add the viscous liquid into a dry heat sterilization box and fill it with nitrogen to seal it, heat the dry heat sterilization box to 180-200°C at a heating rate of 10°C / min, then control the constant temperature for 30-60 minutes for sterilization, and after the sterilization is completed, close the dry heat sterilization box and wait for the internal viscous liquid to naturally cool to room temperature before taking out the sterile viscous liquid.
[0013] A further improvement is that before taking out the sterile viscous liquid, 0.5 ml is sucked out with a pipette in a sterile environment and a sterilization effect test is performed using a biological indicator. After the test is qualified, the sterile viscous liquid is taken out and stored in a sterile tank for standby use.
[0014] A further improvement is that in step 4, the gradient high pressure homogenization treatment pressure is between 800-2000 bar and four evenly increasing gradients are respectively used for four cycles of homogenization treatment, the flow rate is controlled at 150-180 m / s, and the temperature is controlled at 80-100°C.
[0015] The beneficial effects of the present invention are as follows: the suspension of the prepared suspension particles can be made better by adding a suspending agent, and the stability is greatly improved; the addition of acetylcysteine allows the suspension to automatically dissolve the obstruction of sticky phlegm during atomization inhalation, thereby improving the inhalation effect of the medication population; and the suspension effect of the suspension is further increased by nano-grinding after mixing and gradient high-pressure homogenization treatment, and the particle size distribution, sedimentation volume ratio, redispersibility and stability of the prepared budesonide suspension are all improved to varying degrees, making the suspension more suitable for the medication population to absorb. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The figure is a flow chart of a method according to an embodiment of the present invention. DETAILED DESCRIPTION
[0017] In order to deepen the understanding of the present invention, the present invention will be further described in detail below in conjunction with examples. The examples are only used to explain the present invention and do not constitute a limitation on the protection scope of the present invention. Example
[0018] according to Figure 1 As shown, this embodiment provides a budesonide suspension for inhalation, comprising budesonide, edetate disodium, acetylcysteine, a surfactant, sodium chloride, a pH regulator, phenylethanol, sodium hyaluronate and water for injection mixed in a mass ratio of 3.8:0.45:1.5:0.2:4.95:3.8:1.3:1.2:82.8.
[0019] Budesonide Particle Size Range D 90 Less than 8μm, where D 50 Less than 5μm, D 10Less than 3μm; the surfactant is polysorbate 80; the pH adjuster is a mixture of citric acid and sodium citrate in a mass ratio of 1.3:2.5.
[0020] A method for preparing a budesonide suspension for inhalation comprises the following steps: Step 1, preliminary mixing, first weigh budesonide, edetate disodium, acetylcysteine, sodium chloride, citric acid and sodium citrate according to the ratio and add them into a mixing device for stirring and mixing, then place the mixed materials in a nano-grinding device for nano-grinding treatment and sieve to obtain a premix, then add deionized water to dissolve and stir until there is no precipitate to obtain a premixed solution, wherein a 1700-mesh screen is used for sieving.
[0021] Step 2: Mixing and concentrating: adding polysorbate 80 to the premixed solution and stirring to dissolve to obtain a mixed solution, and then evaporating and concentrating the mixed solution to a viscous liquid; The specific operation of evaporation and concentration is to first introduce the mixed solution into the evaporation tank, then extract the air inside it to make it in a low-pressure state, then start the evaporation tank to heat and evaporate the mixed solution, and then naturally cool the evaporated and concentrated viscous liquid to room temperature for collection, thus obtaining a viscous liquid.
[0022] Step 3: sterilization treatment: performing dry heat sterilization on the prepared viscous liquid to obtain a sterile viscous liquid; Dry heat sterilization is to first add the viscous liquid into the dry heat sterilization box and fill it with nitrogen to seal it, heat the dry heat sterilization box to 200℃ at a heating rate of 10℃ / min, and then control the constant temperature for 30min for sterilization. After the sterilization is completed, close the dry heat sterilization box and wait for the internal viscous liquid to naturally cool down to room temperature and take out the sterile viscous liquid; Before taking out the sterile viscous liquid, use a pipette to draw 0.5 ml in a sterile environment and use a biological indicator to test the sterilization effect. After passing the test, take out the sterile viscous liquid and store it in a sterile tank for later use.
[0023] Step 4: diluting and homogenizing, diluting the sterile viscous liquid with 50% of the total amount of water for injection, and then using a high-pressure homogenizer to perform gradient high-pressure homogenization after sufficient stirring and dissolution to obtain a homogenized suspension, and then adding phenylethanol, sodium hyaluronate and the remaining water for injection to the suspension and uniformly mixing to obtain a budesonide suspension; The gradient high-pressure homogenization treatment pressure was 800 bar, 1200 bar, 1600 bar and 2000 bar, and four cycles of homogenization were performed respectively. The flow rate was controlled at 150 m / s, 160 m / s, 170 m / s and 180 m / s, and the temperature was controlled at 80°C, 87°C, 93°C and 100°C.
[0024] Step 5: Test packaging. Perform particle size distribution, sedimentation volume ratio, redispersibility and stability tests on the prepared budesonide suspension. Once the test results meet the standards, sterile filling can be performed. Example
[0025] This embodiment provides a budesonide suspension for inhalation, which is prepared by mixing budesonide, edetate disodium, acetylcysteine, a surfactant, sodium chloride, a pH regulator, chlorobutanol, sodium carboxymethyl cellulose and water for injection in a mass ratio of 5.2:1.2:2:0.1:2.4:4:1.2:0.8:83.1.
[0026] Budesonide Particle Size Range D 90 Less than 8μm, where D 50 Less than 5μm, D 10 Less than 3μm; the surfactant is polysorbate 80; the pH adjuster is a mixture of citric acid and sodium citrate in a mass ratio of 1.5:2.5.
[0027] A method for preparing a budesonide suspension for inhalation comprises the following steps: Step 1, preliminary mixing, first weigh budesonide, edetate disodium, acetylcysteine, sodium chloride, citric acid and sodium citrate according to the ratio and add them into a mixing device for stirring and mixing, then place the mixed materials in a nano-grinding device for nano-grinding treatment and sieve to obtain a premix, then add deionized water to dissolve and stir until there is no precipitate to obtain a premixed solution, wherein a 1700-mesh screen is used for sieving.
[0028] Step 2: Mixing and concentrating: adding polysorbate 80 to the premixed solution and stirring to dissolve to obtain a mixed solution, and then evaporating and concentrating the mixed solution to a viscous liquid; The specific operation of evaporation and concentration is to first introduce the mixed solution into the evaporation tank, then extract the air inside it to make it in a low-pressure state, then start the evaporation tank to heat and evaporate the mixed solution, and then naturally cool the evaporated and concentrated viscous liquid to room temperature for collection, thus obtaining a viscous liquid.
[0029] Step 3: sterilization treatment: performing dry heat sterilization on the prepared viscous liquid to obtain a sterile viscous liquid; Dry heat sterilization is to first add the viscous liquid into the dry heat sterilization box and fill it with nitrogen to seal it, heat the dry heat sterilization box to 180℃ at a heating rate of 10℃ / min, and then control the constant temperature for 60min for sterilization. After the sterilization is completed, close the dry heat sterilization box and wait for the internal viscous liquid to naturally cool down to room temperature and take out the sterile viscous liquid; Before taking out the sterile viscous liquid, use a pipette to draw 0.5 ml in a sterile environment and use a biological indicator to test the sterilization effect. After passing the test, take out the sterile viscous liquid and store it in a sterile tank for later use.
[0030] Step 4: diluting and homogenizing, diluting the sterile viscous liquid with 50% of the total amount of water for injection, and then using a high-pressure homogenizer to perform gradient high-pressure homogenization after sufficient stirring and dissolution to obtain a homogenized suspension, and then adding chlorobutanol, sodium carboxymethyl cellulose and the remaining water for injection to the suspension and uniformly mixing to obtain a budesonide suspension; The gradient high-pressure homogenization treatment pressure was 800 bar, 1200 bar, 1600 bar and 2000 bar, and four cycles of homogenization were performed respectively. The flow rate was controlled at 150 m / s, 160 m / s, 170 m / s and 180 m / s, and the temperature was controlled at 80°C, 87°C, 93°C and 100°C.
[0031] Step 5: Test packaging. Perform particle size distribution, sedimentation volume ratio, redispersibility and stability tests on the prepared budesonide suspension. Once the test results meet the standards, sterile filling can be performed. Example
[0032] This embodiment provides a budesonide suspension for inhalation, which is prepared by mixing budesonide, edetate disodium, acetylcysteine, a surfactant, sodium chloride, a pH regulator, ethylparaben, polyethylene glycol and water for injection in a mass ratio of 5:0.5:3:0.35:2.45:4.8:1.8:1.6:80.5.
[0033] Budesonide Particle Size Range D 90 Less than 8μm, where D 50 Less than 5μm, D 10 Less than 3μm; the surfactant is polysorbate 80; the pH adjuster is a mixture of citric acid and sodium citrate in a mass ratio of 1.8:3.
[0034] A method for preparing a budesonide suspension for inhalation comprises the following steps: Step 1, preliminary mixing, first weigh budesonide, edetate disodium, acetylcysteine, sodium chloride, citric acid and sodium citrate according to the ratio and add them into a mixing device for stirring and mixing, then place the mixed materials in a nano-grinding device for nano-grinding treatment and sieve to obtain a premix, then add deionized water to dissolve and stir until there is no precipitate to obtain a premixed solution, wherein a 1700-mesh screen is used for sieving.
[0035] Step 2: Mixing and concentrating: adding polysorbate 80 to the premixed solution and stirring to dissolve to obtain a mixed solution, and then evaporating and concentrating the mixed solution to a viscous liquid; The specific operation of evaporation and concentration is to first introduce the mixed solution into the evaporation tank, then extract the air inside it to make it in a low-pressure state, then start the evaporation tank to heat and evaporate the mixed solution, and then naturally cool the evaporated and concentrated viscous liquid to room temperature for collection, thus obtaining a viscous liquid.
[0036] Step 3: sterilization treatment: performing dry heat sterilization on the prepared viscous liquid to obtain a sterile viscous liquid; Dry heat sterilization is to first add the viscous liquid into the dry heat sterilization box and fill it with nitrogen to seal it, heat the dry heat sterilization box to 190℃ at a heating rate of 10℃ / min, and then control the constant temperature for 50min for sterilization. After the sterilization is completed, close the dry heat sterilization box and wait for the internal viscous liquid to naturally cool down to room temperature and take out the sterile viscous liquid; Before taking out the sterile viscous liquid, use a pipette to draw 0.5 ml in a sterile environment and use a biological indicator to test the sterilization effect. After passing the test, take out the sterile viscous liquid and store it in a sterile tank for later use.
[0037] Step 4: diluting and homogenizing, diluting the sterile viscous liquid with 50% of the total amount of water for injection, and then using a high-pressure homogenizer to perform gradient high-pressure homogenization after sufficient stirring and dissolution to obtain a homogenized suspension, and then adding ethyl paraben, polyethylene glycol and the remaining water for injection to the suspension and uniformly mixing to obtain a budesonide suspension; The gradient high-pressure homogenization treatment pressure was 800 bar, 1200 bar, 1600 bar and 2000 bar, and four cycles of homogenization were performed respectively. The flow rate was controlled at 150 m / s, 160 m / s, 170 m / s and 180 m / s, and the temperature was controlled at 80°C, 87°C, 93°C and 100°C.
[0038] Step 5: Test packaging. Perform particle size distribution, sedimentation volume ratio, redispersibility and stability tests on the prepared budesonide suspension. Once the test results meet the standards, sterile filling can be performed. Example
[0039] This embodiment provides a measurement experiment using the budesonide suspension for inhalation prepared in Examples 1-3 and a traditional budesonide suspension. The particle size distribution of the suspension is measured using a dynamic light scattering method, and the sedimentation volume ratio of the suspension is processed and detected using an artificial centrifugation method. The redispersibility test of the suspension is uniformly performed by stirring at a speed of 15-20 r / min for 30 seconds and then standing to observe the sediment. The stability test of the suspension places four groups of suspensions in the same environment, and after the temperature change test, the suspension is stood for 6 months and observed and recorded. The temperature change range is between -15°C and 50°C. The test data are shown in Table 1 below.
[0040] It can be seen from Table 1 above that the particle size distribution of the suspension prepared in the present application is relatively balanced, and the particle size distribution is within the range of particles that can be absorbed by the human body, which is more suitable for the full absorption of the particles by the human body and increases the absorption effect; at the same time, the sedimentation volume ratio also meets the requirements; The redispersibility and temperature change tests demonstrate that the suspension prepared in the present application is stable and less affected by temperature changes. Compared with the traditional suspension, which has more sedimentation, the sedimentation in the present application is greatly reduced, and the redispersibility is better than the traditional suspension. After sedimentation, stirring can make the suspension uniform.
[0041] At the same time, after standing for a long time, the sediment of the suspension prepared in the present application is greatly reduced compared with the traditional suspension, which shows that the suspension prepared in the present application has better particle suspension effect and greatly improved stability.
[0042] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A budesonide suspension for inhalation, characterized in that: The invention comprises budesonide, edetate disodium, acetylcysteine, surfactant, sodium chloride, pH regulator, antibacterial agent, suspending agent and water for injection, which are mixed in the mass ratio of 3.5-5.5:0.45-1.25:1.5-3:0.1-0.35:2.4-5.5:3.8-4.8:1.2-1.8:0.8-1.6:75-90.
2. A budesonide suspension for inhalation according to claim 1, characterized in that: The budesonide particle size range D 90 Less than 8μm, where D 50 Less than 5μm, D 10 Less than 3 μm; the surfactant is polysorbate 80; the pH adjuster is a mixture of citric acid and sodium citrate in a mass ratio of 1.3-1.8:2.5-3.
3. A budesonide suspension for inhalation according to claim 1, characterized in that: The antibacterial agent is one or more of ethyl paraben, phenol, phenylethyl alcohol and chlorobutanol; the suspending agent is one or more of sodium carboxymethyl cellulose, polyethylene glycol and sodium hyaluronate.
4. A budesonide suspension for inhalation according to claim 1, characterized in that: The mixing mass ratio of the budesonide, edetate disodium, acetylcysteine, surfactant, sodium chloride, pH regulator, antibacterial agent, suspending agent and water for injection is 3.8:0.45:1.5:0.2:4.95:3.8:1.3:1.2:82.
8.
5. A method for preparing a budesonide suspension for inhalation, characterized in that: The following steps are involved: Step 1: Preliminary mixing: budesonide, edetate disodium, acetylcysteine, sodium chloride, citric acid and sodium citrate are premixed, and then deionized water is added to dissolve and stir until no precipitate is obtained to obtain a premixed solution; Step 2: Mixing and concentrating: adding polysorbate 80 to the premixed solution and stirring to dissolve to obtain a mixed solution, and then evaporating and concentrating the mixed solution to a viscous liquid; Step 3: sterilization treatment: performing dry heat sterilization on the prepared viscous liquid to obtain a sterile viscous liquid; Step 4: diluting and homogenizing, diluting the sterile viscous liquid with 50% of the total amount of water for injection, and then using a high-pressure homogenizer to perform gradient high-pressure homogenization after sufficient stirring and dissolution to obtain a homogenized suspension, and then adding the antibacterial agent, the suspending agent and the remaining water for injection to the suspension and uniformly mixing to obtain a budesonide suspension; Step 5: Test packaging. Perform particle size distribution, sedimentation volume ratio, redispersibility and stability tests on the prepared budesonide suspension. Once the test results meet the standards, sterile filling can be performed.
6. The method for preparing a budesonide suspension for inhalation according to claim 5, characterized in that: The premixing in step 1 specifically includes first weighing the materials according to the proportion and adding them into a mixing device for stirring and mixing, and then placing the mixed materials in a nano-grinding device for nano-grinding treatment and sieving to obtain a premix; wherein a 1700-mesh screen is used for sieving.
7. The method for preparing a budesonide suspension for inhalation according to claim 5, characterized in that: The specific operation of evaporation concentration in step 2 is to first introduce the mixed solution into an evaporation tank, then extract the air inside the evaporation tank to make it in a low-pressure state, then start the evaporation tank to heat and evaporate the mixed solution, and then naturally cool the evaporated and concentrated viscous liquid to room temperature for collection, so as to obtain a viscous liquid.
8. The method for preparing a budesonide suspension for inhalation according to claim 5, characterized in that: In the step 3, the dry heat sterilization is to first add the viscous liquid into a dry heat sterilization box and fill it with nitrogen to seal it, heat the dry heat sterilization box to 180-200°C at a heating rate of 10°C / min, then control the constant temperature for 30-60 minutes for sterilization, and after the sterilization is completed, close the dry heat sterilization box and wait for the internal viscous liquid to naturally cool to room temperature to take out the sterile viscous liquid.
9. The method for preparing a budesonide suspension for inhalation according to claim 8, characterized in that: Before taking out the sterile viscous liquid, 0.5 ml is sucked out with a pipette in a sterile environment and a sterilization effect test is performed using a biological indicator. After the test is qualified, the sterile viscous liquid is taken out and stored in a sterile tank for later use.
10. The method for preparing a budesonide suspension for inhalation according to claim 5, characterized in that: In the step 4, the gradient high pressure homogenization treatment pressure is between 800-2000 bar and four evenly increasing gradients are respectively used for four cycles of homogenization treatment, the flow rate is controlled at 150-180 m / s, and the temperature is controlled at 80-100°C.
